TickerHumSide-by-side comparison
Moderna vs Regeneron Pharmaceuticals
As of Nov 11, 2026, revenue growth is 13.1% for Moderna vs 18.6% for Regeneron Pharmaceuticals; operating margin is -116.0% for Moderna vs 28.8% for Regeneron Pharmaceuticals; net margin is -110.5% for Moderna vs 28.5% for Regeneron Pharmaceuticals; debt/equity is 0.09 for Moderna vs 0.06 for Regeneron Pharmaceuticals.
What stands out
- Regeneron Pharmaceuticals keeps more of each sale as operating profit: 28.8% margin vs -116.0% for Moderna.
- Moderna's shares did better over the past year: +828.8% vs +38.4% for Regeneron Pharmaceuticals.
- Regeneron Pharmaceuticals scores higher on TickerHum's ratings: 78/100 vs 47/100 for Moderna.
Key metrics
| Metric | MRNA | REGN |
|---|---|---|
| Price | $248.09 | $943.71 |
| Market cap | $100.38B | — |
| P/E | — | 20.9x (#1) |
| P/S | 39.8x (#1) | — |
| Revenue growth | 13.1% (#2) | 18.6% (#1) |
| Operating margin | -116.0% (#2) | 28.8% (#1) |
| Net margin | -110.5% (#2) | 28.5% (#1) |
| Debt / equity | 0.09 (#2) | 0.06 (#1) |
| 1-year return | +828.8% (#1) | +38.4% (#2) |
| Research score | 47/100 (#2) | 78/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Moderna, Inc. (MRNA) — Biotechnology
- Regeneron Pharmaceuticals, Inc. (REGN) — Biotechnology